You are viewing the site in preview mode

Skip to main content
Fig. 1 | Annals of Clinical Microbiology and Antimicrobials

Fig. 1

From: Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication

Fig. 1

A flow diagram of proton pump inhibitor-based therapy. Patients who underwent clarithromycin susceptibility testing were treated by either PPI-AC or PPI-AM regimen. PPI-AC therapy was chosen for empirical therapy. PPI-AC proton pump inhibitor with amoxicillin and clarithromycin, PPI-AM proton pump inhibitor with amoxicillin and metronidazole

Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us